• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢癌患者中对化疗反应及DNA修复具有潜在重要性的基因表达

Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer.

作者信息

Codegoni A M, Broggini M, Pitelli M R, Pantarotto M, Torri V, Mangioni C, D'Incalci M

机构信息

Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.

出版信息

Gynecol Oncol. 1997 Apr;65(1):130-7. doi: 10.1006/gyno.1996.4609.

DOI:10.1006/gyno.1996.4609
PMID:9103402
Abstract

The expression of different genes potentially involved in DNA repair and in cell responses to chemotherapy was evaluated in 33 previously untreated ovarian cancer patients. In biopsies of the same patients the expression of repair genes O6-methylguanine DNA methyltransferase (MGMT), 3-methyladenine DNA glycosylase (MAG), ERCC1, MDR-1, DNA topoisomerase I, DNA topoisomerase IIalpha, and glutathione S-transferase-pi (GST-pi) was assessed by Northern blot analysis. No direct statistical correlation was found between the expression of these genes and the response to chemotherapy (mainly platinum-based with or without doxorubicin and cyclophosphamide). Univariate analysis showed a weak negative correlation (P = 0.037) between the expression of ERCC1 and mortality, whereas no statistically significant correlation was found for other parameters. The MDR-1 gene encoding for the P-glycoprotein P-170 was mostly undetectable in these patients (as assessed by Northern blotting), whereas relatively high levels of MAG and MGMT were found in the majority of patients. A statistically significant correlation was found between the expression of DNA topoisomerase I and the expression of either ERCC1 (P = 0.0026) or GST-pi (P = 0.0279).

摘要

在33例未经治疗的卵巢癌患者中,评估了可能参与DNA修复及细胞对化疗反应的不同基因的表达情况。通过Northern印迹分析,对同一批患者活检样本中修复基因O6-甲基鸟嘌呤DNA甲基转移酶(MGMT)、3-甲基腺嘌呤DNA糖基化酶(MAG)、ERCC1、多药耐药基因1(MDR-1)、DNA拓扑异构酶I、DNA拓扑异构酶IIα和谷胱甘肽S-转移酶π(GST-π)的表达进行了评估。未发现这些基因的表达与化疗反应(主要是含或不含阿霉素及环磷酰胺的铂类化疗)之间存在直接的统计学相关性。单因素分析显示,ERCC1的表达与死亡率之间存在微弱的负相关性(P = 0.037),而其他参数未发现有统计学意义的相关性。编码P-糖蛋白P-170的MDR-1基因在这些患者中大多检测不到(通过Northern印迹法评估),而大多数患者中发现MAG和MGMT的水平相对较高。DNA拓扑异构酶I的表达与ERCC1(P = 0.0026)或GST-π(P = 0.0279)的表达之间存在统计学显著相关性。

相似文献

1
Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer.卵巢癌患者中对化疗反应及DNA修复具有潜在重要性的基因表达
Gynecol Oncol. 1997 Apr;65(1):130-7. doi: 10.1006/gyno.1996.4609.
2
Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.多药耐药相关蛋白P-糖蛋白、谷胱甘肽-S-转移酶、拓扑异构酶-II和肺耐药蛋白在原发性胃贲门腺癌中的表达
Cancer Invest. 2008 May;26(4):344-51. doi: 10.1080/07357900701788072.
3
A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.一项妇科肿瘤学组关于铂-DNA加合物及切除修复交叉互补组1表达情况的研究,该研究针对接受铂-紫杉烷化疗的Ⅲ期上皮性卵巢癌患者,处于最佳状态。
Cancer Res. 2007 May 1;67(9):4474-81. doi: 10.1158/0008-5472.CAN-06-4076.
4
Multiple drug resistance parameter expression in ovarian cancer.卵巢癌中多药耐药参数的表达
Gynecol Oncol. 1998 Aug;70(2):176-82. doi: 10.1006/gyno.1998.5085.
5
Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.c-erbB-2和拓扑异构酶IIα在卵巢癌化疗耐药中的作用
Cancer Res. 1999 Jul 1;59(13):3206-14.
6
Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line.5-氟尿嘧啶对顺铂耐药的HST-1人鳞状癌细胞系中ERCC1和γ-谷氨酰半胱氨酸合成酶信使核糖核酸表达的抑制作用
Oncol Res. 1997;9(4):167-72.
7
ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.上皮性卵巢癌中的ERCC1基因型和表型可识别出除铂类疗法外可能从紫杉醇治疗中获益的患者。
J Clin Oncol. 2007 Nov 20;25(33):5172-9. doi: 10.1200/JCO.2007.11.8547.
8
Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.多药耐药相关蛋白P-糖蛋白、谷胱甘肽-S-转移酶、拓扑异构酶-II和肺耐药蛋白在原发性胃贲门腺癌中的表达
Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1530-6.
9
High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.TS1、GSTP1和ERCC1的高基因表达是接受食管癌三联疗法治疗患者生存的危险因素。
Clin Cancer Res. 2005 Mar 15;11(6):2215-21. doi: 10.1158/1078-0432.CCR-04-1387.
10
Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.卵巢癌组织中XPAC和ERCC1的信使核糖核酸水平与铂类化疗的反应相关。
J Clin Invest. 1994 Aug;94(2):703-8. doi: 10.1172/JCI117388.

引用本文的文献

1
Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.ABCB1在上皮性卵巢癌化疗中的预后价值及意义:一项Meta分析
PLoS One. 2016 Nov 3;11(11):e0166058. doi: 10.1371/journal.pone.0166058. eCollection 2016.
2
ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine.ERCC1和RRM1作为接受顺铂和/或吉西他滨治疗的非小细胞肺癌、卵巢癌或胰腺癌的预测参数。
Contemp Oncol (Pozn). 2015;19(3):207-13. doi: 10.5114/wo.2015.52656. Epub 2015 Jul 8.
3
Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies.
几种生物标志物在卵巢上皮性癌中的预后意义:已发表研究的荟萃分析。
J Cancer Res Clin Oncol. 2013 Aug;139(8):1257-77. doi: 10.1007/s00432-013-1435-z. Epub 2013 Apr 18.
4
Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.晚期卵巢癌患者接受腹腔内铂类药物治疗后,ERCC1/XPF 基因变异、mRNA 和蛋白水平的比较
Gynecol Oncol. 2012 Sep;126(3):448-54. doi: 10.1016/j.ygyno.2012.05.006. Epub 2012 May 16.
5
Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy.核孔结构的改变使癌细胞能够进入或退出耐药休眠状态。
Am J Pathol. 2012 Jan;180(1):375-89. doi: 10.1016/j.ajpath.2011.09.024. Epub 2011 Nov 7.
6
Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy.腹膜癌转移来自卵巢癌:化疗敏感性测试和组织标志物可预测化疗反应。
J Transl Med. 2011 Jun 20;9:94. doi: 10.1186/1479-5876-9-94.
7
Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy.检测 ERCC1 表达对接受以顺铂为基础的一线化疗的晚期胃癌患者治疗反应和生存的预测价值。
Cancer Res Treat. 2010 Jun;42(2):101-6. doi: 10.4143/crt.2010.42.2.101. Epub 2010 Jun 30.
8
Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.III 期卵巢浆液性癌化疗耐药的潜在预测标志物。
BMC Cancer. 2009 Oct 18;9:368. doi: 10.1186/1471-2407-9-368.
9
Increased ERCC expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer.ERCC 表达增加与接受顺铂辅助治疗可切除胃癌患者的预后改善相关。
Cancer Res Treat. 2006 Feb;38(1):19-24. doi: 10.4143/crt.2006.38.1.19. Epub 2006 Feb 28.
10
Mechanisms of resistance to alkylating agents.烷基化试剂耐药机制。
Cytotechnology. 1998 Sep;27(1-3):165-73. doi: 10.1023/A:1008060720608.